Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer
- Author
- VON PAWEL, Joachim; GATZEMEIER, Ulrich; LANE, Stephen; ROSS, Graham; PUJOL, Jean-Louis; MOREAU, Lionel; BILDAT, S; RANSON, Malcolm; RICHARDSON, Gary; STEPPERT, Claus; RIVIERE, Alain; CAMLETT, Ina
Asklepios Fachklinik, Gauting bei München, Munich, Germany
Centre François Baclesse, Caen, France
Centre Hospitalier Universitaire Hôpital Lyautey, Strasbourg, France
Christie Hospital, Manchester, United Kingdom
Hospital of Diseases of Respiratory Organs, Ebensfield, Germany
Hôpital Arnaud de Villeneuve, Montpellier, France
Krankenhaus Grosshansdorf, Grosshansdorf, Germany
Monash Medical Centre, Clayton, Australia
SmithKline Beecham Pharmaceuticals, Collegeville, PA, United States
SmithKline Beecham Pharmaceuticals, Harlow, United Kingdom
West German Cancer Centre, Essen, Germany - Source
Journal of clinical oncology. 2001, Vol 19, Num 6, pp 1743-1749 ; ref : 13 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Bronchopulmonaire Carcinome petite cellule Chimiothérapie Complication DNA topoisomerase Efficacité traitement Essai clinique phase II Etude comparative Homme Inhibiteur enzyme Topotécane Toxicité Traitement Voie administration Voie intraveineuse Voie orale Pyrano indolizino quinoléine dérivé Appareil respiratoire pathologie Bronche pathologie Enzyme Isomerases Poumon pathologie Tumeur maligne
- Keyword (en)
- Antineoplastic agent Bronchopulmonary Small cell carcinoma Chemotherapy Complication DNA topoisomerase Treatment efficiency Phase II trial Comparative study Human Enzyme inhibitor Topotecan Toxicity Treatment Route of administration Intravenous administration Oral administration Respiratory disease Bronchus disease Enzyme Isomerases Lung disease Malignant tumor
- Keyword (es)
- Anticanceroso Broncopulmonar Carcinoma célula de avena Quimioterapia Complicación DNA topoisomerase Eficacia tratamiento Ensayo clínico fase II Estudio comparativo Hombre Inhibidor enzima Topotecán Toxicidad Tratamiento Vía administración Vía intravenosa Vía oral Aparato respiratorio patología Bronquio patología Enzima Isomerases Pulmón patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 936627
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2001.19.6.1743 
https://dx.doi.org/10.1200/JCO.2001.19.6.1743
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.2001.19.6.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1749\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"VON PAWEL\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Joachim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:18:\"GATZEMEIER, Ulrich\";i:1;s:13:\"LANE, Stephen\";i:2;s:12:\"ROSS, Graham\";i:3;s:17:\"PUJOL, Jean-Louis\";i:4;s:14:\"MOREAU, Lionel\";i:5;s:9:\"BILDAT, S\";i:6;s:15:\"RANSON, Malcolm\";i:7;s:16:\"RICHARDSON, Gary\";i:8;s:15:\"STEPPERT, Claus\";i:9;s:14:\"RIVIERE, Alain\";i:10;s:12:\"CAMLETT, Ina\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.2001.19.6.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1749\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"VON PAWEL\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Joachim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:18:\"GATZEMEIER, Ulrich\";i:1;s:13:\"LANE, Stephen\";i:2;s:12:\"ROSS, Graham\";i:3;s:17:\"PUJOL, Jean-Louis\";i:4;s:14:\"MOREAU, Lionel\";i:5;s:9:\"BILDAT, S\";i:6;s:15:\"RANSON, Malcolm\";i:7;s:16:\"RICHARDSON, Gary\";i:8;s:15:\"STEPPERT, Claus\";i:9;s:14:\"RIVIERE, Alain\";i:10;s:12:\"CAMLETT, Ina\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.2001.19.6.1743\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.2001.19.6.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1749\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"VON PAWEL\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Joachim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:18:\"GATZEMEIER, Ulrich\";i:1;s:13:\"LANE, Stephen\";i:2;s:12:\"ROSS, Graham\";i:3;s:17:\"PUJOL, Jean-Louis\";i:4;s:14:\"MOREAU, Lionel\";i:5;s:9:\"BILDAT, S\";i:6;s:15:\"RANSON, Malcolm\";i:7;s:16:\"RICHARDSON, Gary\";i:8;s:15:\"STEPPERT, Claus\";i:9;s:14:\"RIVIERE, Alain\";i:10;s:12:\"CAMLETT, Ina\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.2001.19.6.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1749\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"VON PAWEL\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Joachim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:18:\"GATZEMEIER, Ulrich\";i:1;s:13:\"LANE, Stephen\";i:2;s:12:\"ROSS, Graham\";i:3;s:17:\"PUJOL, Jean-Louis\";i:4;s:14:\"MOREAU, Lionel\";i:5;s:9:\"BILDAT, S\";i:6;s:15:\"RANSON, Malcolm\";i:7;s:16:\"RICHARDSON, Gary\";i:8;s:15:\"STEPPERT, Claus\";i:9;s:14:\"RIVIERE, Alain\";i:10;s:12:\"CAMLETT, Ina\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.2001.19.6.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1749\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"VON PAWEL\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Joachim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:18:\"GATZEMEIER, Ulrich\";i:1;s:13:\"LANE, Stephen\";i:2;s:12:\"ROSS, Graham\";i:3;s:17:\"PUJOL, Jean-Louis\";i:4;s:14:\"MOREAU, Lionel\";i:5;s:9:\"BILDAT, S\";i:6;s:15:\"RANSON, Malcolm\";i:7;s:16:\"RICHARDSON, Gary\";i:8;s:15:\"STEPPERT, Claus\";i:9;s:14:\"RIVIERE, Alain\";i:10;s:12:\"CAMLETT, Ina\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
